Key result
Treatment with newer ECMO technology (Era 3) was associated with improved survival to hospital discharge compared to the overall cohort (52.6% vs 44.4%, P<0.003).
Why the study?
Does newer ECMO technology improve survival to hospital discharge in pediatric patients requiring extracorporeal support?
Cohort (n=275)
No
Does newer ECMO technology improve survival to hospital discharge in pediatric patients requiring extracorporeal support?
Absolute Event Rate: 52.6% vs 44.4%
p-value: p=<0.003
Newer ECMO technology is associated with improved survival to intensive care discharge and reduced mechanical circuit complications in pediatric patients.
Newer ECMO may merit evaluation in pediatric support; leaves open confirmation by randomized trials before practice change.
This study aims to evaluate the impact of a change in extracorporeal membrane oxygenation (ECMO) technology on patient and circuit outcomes. A retrospective single-centre study of all ECMO runs from 1988 to 2006 was performed. Predictors of survival to hospital discharge (primary outcome measure) were evaluated in the entire cohort by univariate and multivariate analysis. A detailed subgroup univariate and multivariate analysis was performed in the cardiac and respiratory groups to identify predictors of survival to hospital discharge. A total of 275 patients underwent 294 extracorporeal support runs at a median (interquartile range) age of 40 (3-639) days and weight of 4.0 (3.1-10) kg. The primary indications for support were respiratory (41.8%), cardiac (45.6%) and sepsis (12.6%). Between the initial (Era 1) and most recent era (Era 3), cardiac support became the predominant ECMO indication (26 of 127 vs. 59 of 107; P<0.001). Survival to decannulation, intensive care and hospital discharge for the entire cohort and Era 3 patients were 50.0%, 48.9%, 44.4% and 71.7%, 55.6%, 52.6% (P<0.003), respectively. Treatment in Era 3 was associated with increased survival to intensive care discharge (P=0.02) for all ECMO patients. Cardiac survival was associated with treatment in Era 3 (P=0.04) and a lower complexity score (P<0.001). There was a significant reduction in mechanical circuit complications in the respiratory ECMO subgroup. A significant improvement in patient survival outcomes and reduction in mechanical circuit complications was noted in the current era. This improvement was associated with a change in ECMO technology.
No takes yet. Share an insight, caveat, or question.
Sivarajan et al. (2010) conducted a cohort in Paediatric patients requiring extracorporeal membrane oxygenation (ECMO) (n=275). Newer ECMO technology (Era 3) vs. Entire cohort / Initial era (Era 1) was evaluated on Survival to hospital discharge (p=<0.003). Treatment with newer ECMO technology (Era 3) was associated with improved survival to hospital discharge compared to the overall cohort (52.6% vs 44.4%, P<0.003).
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: